The Oupicky Lab – Advanced Drug and Gene Delivery

Oupicky Lab Group photo 2016

David Oupicky, PhD

Welcome

The Oupicky Lab focuses on exploring polymers and nanoparticles for delivery of drugs and nucleic acids. We are especially interested in pharmacologically active polymers (polymeric drugs) and in delivery vectors suitable for delivery of drug/gene, drug/siRNA, and drug/miRNA combinations in the treatment of acute kidney injury, metastatic cancer, liver and lung fibrosis, and inflammatory bowel disease.

News

Our new paper on the determinants of preferential renal accumulation of synthetic polymers in acute kidney injury has been accepted for publication in the International Journal of Pharmaceutics. Congratulations to Yi and her coauthors., July 2019
Weimin and Yu received UNMC Graduate Fellowships. Congratulations, July 2019
Karen Pennington joined the lab as a lab manager and technologist. Welcome, July 2019
Dr. Diptesh Sil joined the lab as a new postdoc. Welcome, June 2019
The Oupicky lab received a new 5-year R01 from NIAAA to develop miRNA treatments of alcohol-associated liver disease, June 2019
The Oupicky lab received a new grant from the Nebraska Department of Health & Human Services to develop inhalation treatments of lung cancer, June 2019
Prof. Oupicky received the 2019 Outstanding Mentor of Graduate Students award, April 2019
The Oupicky lab received a new 5-year R01 from the NCI to develop polyamine miRNA delivery systems in collaboration with Prof. Casero of Johns Hopkins University, March 2019
Congratulations to Lee Sleightholm for successfully defending his PhD dissertation on repurposing chloroquine for pancreatic cancer treatment. Good luck in finishing the MD part of the MD/PhD program., February 2019

Selected Recent Publications

Y. Xie, Y. Wang, J. Li, Y. Hang, L. Jaramillo, C. J. Wehrkamp, M. A. Phillippi, A. M. Mohr, Y. Chen, G. A. Talmon, J. L. Mott, D. Oupicky. Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness. Theranostics, 2018, 8, 4305-4320

S. Kanvinde, Y. S. Chhonker, R. Ahmad, F. Yu, R. Sleightholm, W. Tang, L. Jaramillo, Y. Chen, Y. Sheinin, J. Li, D. J. Murry, A. B. Singh, D. Oupicky. Pharmacokinetics and efficacy of orally administered polymeric chloroquine as macromolecular drug in the treatment of inflammatory bowel disease. Acta Biomaterialia, 2018, 82, 158-170

G. Chen, Y. Wang, P. Wu, Y. Zhou, F. Yu, C. Zhu, Z. Li, Y. Hang, K. Wang, J. Li, M. Sun, D. Oupicky. Reversibly Stabilized Polycation Nanoparticles for Combination Treatment of Early- and Late-Stage Metastatic Breast Cancer. ACS Nano, 2018, 12, 6620-6636

Y. Xie, T. Murray-Stewart, Y. Wang, F. Yu, J. Li, L. J. Marton, R. A. Casero, D. Oupicky. Self-immolative nanoparticles for simultaneous delivery of microRNA and targeting of polyamine metabolism in combination cancer therapy. Journal of Controlled Release, 2017, 246, 110-119

F. Yu, J. Li, R. L. Sleightholm, Y. Xie, D. Oupicky. Polymeric chloroquine as an inhibitor of cancer cell migration and experimental lung metastasis. Journal of Controlled Release, 2016, 244, 347-356